Short Bowel Syndrome Market: Industry Analysis and Forecast 2027: By Drug Type, Distribution Channel and Region.

Short Bowel Syndrome Market was valued US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a XX% CAGR of around XX% during a forecast period.


Short bowel syndrome affect the functional ability of intestine. Patients suffering from short bowel syndrome have a decreased capability to absorb trace elements, vitamins, fats, fluids, minerals and carbohydrates and can experience weight loss, malnutrition, diarrhea and dehydration. Currently, there is no treatment for short bowel syndrome but the treatment is directed towards symptoms. In a rare cases, short bowel syndrome is life-threatening but usually, the disease can treated through effective medication. Treatment mostly comprises nutrition & diet management, medication and surgery. In treatment, Teduglutide was first permitted by the FDA for short bowel syndrome disorder and other treatments contain antidiarrheal, proton pump, inhibitors histamine blockers, and growth hormones.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The scope of the report includes a detailed study of global and regional markets for Short Bowel Syndrome with the reasons given for variants in the growth of the industry in certain regions.
Growing awareness and convenience of epidemiological data lead to the improved controlling of short bowel disease. Additionally, rapid developments in the field of healthcare have raised awareness about short bowel syndrome and thus, creates opportunities in future. Similarly, non-profit organizations are encouraging research & development about short bowel syndrome in joint scientific research among the public and private sector. In relationship with non-profit organizations, state governments offer special incentives to manufacturers for the improvement of short bowel syndrome drugs. The expansion of short bowel syndrome drugs is at an emerging stage, which generates more opportunities for global players. Public-private partnerships are inspiring pharmaceutical companies to improve new orphan drugs for short bowel syndrome. Few countries have executed a combination of legislations, regulations, and policies indorsing drug development for short bowel syndrome. These are the potential drivers for the growth of the short bowel syndrome market. Instead of this, a lack of sanctioned treatment options may lead to the down regulate the growth of short bowel syndrome market.

The report on Short Bowel Syndrome market covers segments such as by Drug Type, Distribution Channel and Region. The Drug Type segment includes Glucagon-like Peptide, Anti-Diarrheals, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, and Others. Among the Drug Type, Glucagon-like Peptide is accounted for the largest XX% share in the Short Bowel Syndrome market. Currently, Glucagon-Like Peptide is leading the market because of its wide presence in the U.S. and Europe. The Distribution Channel segment is further sub-segmented into Hospital Pharmacies, Specialty Pharmacies, and Others. Among the Distribution Channel, Hospital Pharmacies is accounted for the largest XX% market share in the Short Bowel Syndrome market. The Hospital Pharmacies from Distribution Channel segment is anticipated to have a reasonable growth during the forecasted period.


Based on regional segment, the Short Bowel Syndrome market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the market during forecasted period. The rising prescriptions for Glucagon-like Peptide treatment in the U.S. is anticipated to driver the growth for the North America short bowel syndrome market. Additionally, the fact that glutamine and growth hormone are only permitted in the U.S. for treating SBS is anticipated to keep North America in the lead. The increasing awareness about short bowel syndrome amongst consumers and outstanding reimbursement strategies are anticipated to fuel the regional market during forecast period.

Key players operating in the Short Bowel Syndrome market are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, Zealand Pharma A/S, Swedish Orphan Biovitrum AB, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca Plc, and Johnson & Johnson. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Short Bowel Syndrome market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Short Bowel Syndrome market.
Scope of the Short Bowel Syndrome Market

Short Bowel Syndrome Market, By Drug Type

• Glucagon-like Peptide
• Anti-Diarrheals
• Histamine Blockers
• Proton Pump Inhibitors
• Growth Hormone
• Others
Short Bowel Syndrome Market, By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Others.
Short Bowel Syndrome Market, By Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America
Key players operating in the Global Short Bowel Syndrome Market

• Ardelyx, Inc.
• Emmaus Life Sciences, Inc.
• GLyPharma Therapeutic, Inc.
• Merck KGaA
• Naia Pharmaceuticals, Inc.
• Nutrinia Ltd.
• OxThera, Sancilio & Company, Inc.
• Shire plc.
• Zealand Pharma A/S.
• Swedish Orphan Biovitrum AB.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• AstraZeneca Plc.
• Johnson & Johnson


Chapter One: Short Bowel Syndrome Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Short Bowel Syndrome Market Competition, by Players

Chapter Four: Global Short Bowel Syndrome Market Size by Regions

Chapter Five: North America Short Bowel Syndrome Revenue by Countries

Chapter Six: Europe Short Bowel Syndrome Revenue by Countries

Chapter Seven: Asia-Pacific Short Bowel Syndrome Revenue by Countries

Chapter Eight: South America Short Bowel Syndrome Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Short Bowel Syndrome by Countries

Chapter Ten: Global Short Bowel Syndrome Market Segment by Type

Chapter Eleven: Global Short Bowel Syndrome Market Segment by Application

Chapter Twelve: Global Short Bowel Syndrome Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Short Bowel Syndrome Market Report at:

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage



Contact: +919607065656/ +919607195908